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Human immunodeficiency virus type 1 (HIV-1) binds to the human CD4 (hCD4) and a coreceptor to enter permissive human cells. The
chemokine receptors, hCCR5 and hCXCR4, are the primary coreceptors used by HIV-1 isolates in vivo, however, hCCR3 has been
implicated as a coreceptor for HIV infection of the central nervous system. To determine the domains and amino acids important in hCCR3
coreceptor activity, chimeras between the permissive hCCR3 and the non-permissive rhesus macaque CCR3 (RhCCR3) were constructed and
assessed for coreceptor activity for two R5 strains of HIV-1 (YU-2 and ADA) and one R5X4 strain (89.6). Even though three extracellular
domains of CCR3 participated in coreceptor activity for the two R5 isolates (ECD-1, ECD-3, and ECD-4), for the R5X4 isolate, ECD-4, and
to a lesser extent ECD-3, were critical for coreceptor activity. In addition, residues 13 and 20 in ECD-1, residue 179 in ECD-3, and residue in
271 in ECD-4 of CCR3 were identified for HIV-1 envelope-mediated entry for R5 isolates. In contrast, all the residues on ECD-4 appeared
necessary for coreceptor activity for HIV-189.6. Therefore, multiple residues on multiple extracellular domains of hCCR3 are important for
coreceptor activity for HIV-1.
D 2004 Elsevier Inc. All rights reserved.
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Although human CD4 (hCD4) is the primary receptor
used by the human immunodeficiency virus type 1 (HIV-1)
for infection, it is not sufficient to mediate viral entry into
human cells (Ross et al., 1999). The chemokine receptor,0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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27858, USA.human CXCR4 (hCXCR4), was identified as a coreceptor
with hCD4 as necessary for HIV-1 entry into susceptible
cells (Bleul et al., 1996; Feng et al., 1996; Oberlin et al.,
1996). However, hCXCR4 mediates infection only for
isolates with a specific tropism for T cells and T-cell lines,
known as T-tropic or X4 isolates. The human CCR5
(hCCR5) mediates entry for isolates with specific tropism
for macrophages, known as M-tropic or R5 isolates
(Alkhatib et al., 1997; Choe et al., 1996; Deng et al.,
1996; Doranz et al., 1996; Dragic et al., 1996). hCCR5 and/
or hCXCR4 support virus entry for the vast majority of
primary HIV-1 isolates (Bjorndal et al., 1997; Connor et al.,
1997; Zhang et al., 1996). However, other chemokine
receptors such as CCR2, CCR3, CCR8, CCR9, or CX3CR1,
as well as several orphan receptors (such as STRL33/
BONZO, GPR1, GPR15/BOB and APJ) function as co-
receptors for HIV-1 infection (reviewed in (Philpot, 2003;04) 109–118
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HIV-1 can function to some extent in vitro for virus entry or
envelope-mediated cell–cell fusion. It is yet unclear,
however, how these receptors function in vivo and what
impact these receptors have on the pathogenesis associated
with HIV-1 infection. Potentially, the use of coreceptors
other than hCCR5 or hCXCR4 could enable virus strains to
infect a wider spectrum of cell types, including cells in the
central nervous system, thymus, and mucosa.
The human chemokine receptor, CCR3 (hCCR3), was
shown to serve as a coreceptor for HIV-1 binding and entry
into target cells (Choe et al., 1996; He et al., 1997; Rana et
al., 1997). hCCR3 is expressed predominately on eosino-
phils, microglial cells, basophils, and a subset of T cells
(Berger et al., 1999; Philpot, 2003). This chemokine
receptor has been implicated in HIV-1 infection of cells in
the central nervous system (CNS) (reviewed in (Gorry et al.,
2003; Martin-Garcia et al., 2002). Neurotropism by HIV-1
can cause dementia and other neurological disorders in
AIDS patients (Lipton and Gendelman, 1996; Siliciano,
1999). However, only 20–30% of HIV-1-infected individ-
uals develop AIDS dementia and the underlying causes of
this complex are unclear (Gorry et al., 2003; Martin-Garcia
et al., 2002). Unique to AIDS dementia, compared to other
causes of encephalitis, neuronal injury is not a direct result
of viral infection of neurons, but as a consequence of
indirect mechanisms (Gendelman et al., 1997; Genis et al.,
1992; Lipton, 1997; McArthur et al., 2003). The hCCR5 is
the major M-tropic coreceptor for HIV-1, not only of
macrophages in the peripheral immune system, but also for
those viruses isolated in the brain (Albright et al., 1999;
Choe et al., 1996; He et al., 2003; Li et al., 1999; Shieh et
al., 1998; Smit et al., 2001). Both hCCR5 and hCCR3 are
expressed on resident macrophages in the CNS, the micro-
glia (He et al., 2003). In some patients, disease progression
is associated with a broadening of HIV-1 tropism as a result
of expanded coreceptor usage (Connor et al., 1997).
Recently, Gorry et al. (2001) demonstrated that M-tropism,
regardless of coreceptor usage, is directly associated with
HIV-1 infection of the brain and therefore M-tropism, rather
than hCCR5 usage, predicts HIV-1 microglia infection and
neurotropism.
Compared to hCCR5 and hCXCR4, the domains and
amino acid residues critical for HIV-1 envelope binding
and entry into cells via hCCR3 are not as well understood.
Even though hCCR3 efficiently serves as a coreceptor for
HIV-1 M-tropic and dual tropic isolates, the rhesus
macaque homologue (RhCCR3) does not efficiency serve
as a coreceptor (Sol et al., 1998). In this report, chimeras
between the permissive hCCR3 and the non-permissive
RhCCR3 were constructed and assayed for coreceptor
activity using an R5 and R5X4 molecular clone. In
addition, point mutations were engineered into the
chimeras to determine important residues in the four
extracellular domains (ECD) of hCCR3 necessary to
mediate infection.Results
Construction of chimeric human and rhesus macaque CCR3
This study was designed to identify regions in each of the
four extracellular domains of CCR3 critical for coreceptor
activity. The human CCR3, in conjunction with the hCD4,
mediates HIV-1 entry into human cells (Albright et al.,
1999; Choe et al., 1996; Park et al., 1999; Sol et al., 1998).
In contrast, cells expressing the rhesus macaque homologue
of CCR3 alone or in conjunction with hCD4 does not
mediate viral entry (Sol et al., 1998). Ninety-two percent of
the amino acids are identical between human and rhesus
macaque CCR3. Seventeen of the 102 amino acids (17%) on
the four extracellular domains, which are mostly likely
necessary to mediate HIV-1 envelope binding and fusion,
differ between the two CCR3 molecules (Fig. 1A). There
are six residues that differ between hCCR3 and RhCCR3 in
the first extracellular domain, three in the second, five in the
third, and three in the fourth. Therefore, to determine the
amino acids critical for coreceptor activity by CCR3, three
sets of 14 chimeric hCCR3/RhCCR3 genes were con-
structed using unique restriction enzyme sites (Fig. 1B) and
tested for the ability to mediate HIV-1 entry. Each chimeric
CCR3 receptor was efficiently expressed on the surface of
cells following transient transfection with plasmid DNA
(Table 1).
Single extracellular domains from hCCR3 can confer HIV-1
coreceptor activity to RhCCR3
To determine coreceptor activity of each chimeric CCR3,
different R5 and R5X4 isolates of HIV-1 were used in a
single round infection assay (Ross and Cullen, 1998; Ross et
al., 1998). The hCCR3 efficiently mediated viral entry, in
conjunction with hCD4, with similar efficiency as hCCR5
for all the isolates tested (Fig. 2). In contrast, RhCCR3 does
not serve as a coreceptor for any of the viruses (Fig. 2). The
R5 isolates infected 293T cells expressing the chimeric
hCCR3/RhCCR3 with the first (HRRR), third (RRHR), and
fourth (RRRH) extracellular domain of hCCR3 expressed in
the RhCCR3 backbone (Figs. 2A–B). For each of two R5
isolates, coreceptor activity was less efficient using RRRH
compared to HRRR or RRHR. Cells expressing receptors
with the second extracellular domain (RHRR) from human
CCR3 were not able to mediate viral entry and infection,
even though all receptors were expressed at similar levels
(Table 1). Interestingly, R5X4 isolate, HIV-189.6, was able to
efficiently infect cells expressing only the RRRH in
conjunction with hCD4 cells (Fig. 2C). Therefore, the first,
third, and to a lesser extent, the fourth extracellular domains
of hCCR3 are sufficient to mediate HIV-1 infection for the
R5-tropic viruses when inserted into an otherwise non-
permissive RhCCR3 context. However, only the fourth
domain of hCCR3 confers coreceptor activity to RhCCR3
for HIV-189.6.
Fig. 1. Panel A: primary amino acid sequences of the human and rhesus macaque CCR3. The top line represents the hCCR3 amino acid sequence and the
bottom line represents the RhCCR3 amino acid sequence. Letters in bold represent the amino acids in each of the four extracellular domains of CCR3. The
underlined letters indicate amino acid differences between human and rhesus macaque CCR3. Panel B: schematic of human–rhesus macaque CCR3 chimeras.
The CCR3 is composed of four extracellular domains (I–IV), seven transmembrane domains, and four intracellular domains. The white circles denote amino
acid sequence differences between human and rhesus macaque CCR3.
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Table 1
Expression of cell surface coreceptors
Receptors Mean fluorescence
hCCR3 139.82 F 1.5
RhCCR3 134.76 F 8.5
HRRR 139.93 F 0.2
RHRR 112.27 F 9.1
RRHR 140.80 F 1.0
RRRH 143.17 F 2.1
RHHH 139.93 F 0.6
HRHH 140.05 F 3.6
HHRH 136.86 F 4.2
HHHR 144.85 F 4.6
HHRR 140.50 F 0.8
RRHH 105.00 F 12.0
HRHR 141.21 F 0.8
RHRH 142.75 F 1.5
HRRH 138.60 F 1.5
RHHR 140.82 F 2.9
T13P 142.51 F 1.4
Y17D 142.56 F 1.4
V20M 143.10 F 1.4
T29V 141.21 F 0.5
R30G 141.85 F 1.5
M33I 141.12 F 1.8
E173G 145.69 F 3.5
E176K 144.71 F 2.5
E179P 139.80 F 2.5
L180I 137.72 F 1.8
E189Q 137.02 F 2.5
S263T 142.50 F 1.5
I267V 151.09 F 3.5
N271L 136.32 F 2.4
Vector 5.56 F 0.1
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HIV-1 coreceptor activity of hCCR3
To determine if the introduction of rhesus macaque
CCR3 extracellular domains into the permissive hCCR3
receptor would knockout coreceptor function, a second set
of chimeric receptors was constructed to express a single
domain of RhCCR3 in the hCCR3 backbone. Cells
expressing hCD4 and the chimeric receptors, RHHH,
HRHH, and HHHR, each served as a coreceptor for the
R5 isolates. Once again, a substitution of the fourth ECD
resulted in slightly lower levels of activity (Figs. 3A–B). In
addition, cells expressing the third extracellular domain of
RhCCR3 in hCCR3 (HHRH) did not mediate infection by
R5 isolates. In contrast, only cells expressing the first ECD
of RhCCR3 (RHHH) could efficiently serve as a coreceptor
for HIV-189.6 (Fig. 3C). HRHH, in conjunction with hCD4,Fig. 2. Analysis of the levels of HIV-1 coreceptor activities displayed by
chimeric CCR3 expressing one human extracellular domain in a rhesus
macaque CCR3 backbone. All cells expressed hCD4 and one of the CCR3
molecules. Coreceptor activity was normalized to 100% for hCCR3. Data
are represented as the average of three independent experiments with
standard deviations. Panel A: coreceptor activity was assayed for HIV-1YU-2.
Panel B: coreceptor activity was assayed for HIV-1ADA. Panel C: coreceptor
activity was assayed for HIV-189.6.
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wild type hCCR3 for HIV-189.6 (Fig. 3C). Therefore, the
presence of the third and fourth ECDs of hCCR3 is critical
for coreceptor activity for all the isolates.
Combination of any two extracellular domains confers
CCR3 coreceptor activity for the R5-tropic viruses, but not
for the R5X4-tropic isolate
The next set of chimeras (HHRR, RRHH, HRHR, HRRH,
RHHR, RHRH) each contained two extracellular domains
from hCCR3 and two from RhCCR3. 293T cells expressing
any of these chimeric CCR3s served as a coreceptor for R5
isolates (Fig. 4). However, only the RRHH receptor
efficiently mediated HIV-189.6 entry (Fig. 4). Thus, the third
and fourth extracellular domains once again appear neces-
sary and sufficient to confer coreceptor activity for HIV-189.6.
Mutational analysis of hCCR3/RhCCR3 chimeric receptors
Using an approach that our laboratory and others have
used to map residues in hCCR5 important for coreceptor
activity (Bieniasz et al., 1997; Chabot and Broder, 2000; Lu et
al., 1997; Picard et al., 1997; Ross et al., 1998; Sol et al.,
1998), a series of point mutations were engineered into the
hCCR3/RhCCR3 chimeric receptors to determine which
residues are critical for activity. Mutations were introduced in
the chimeras expressing a single human extracellular domain
in the RhCCR3 backbone. Each mutation was chosen to
substitute the amino acid residue located at the same position
in the RhCCR3 domain. For example, there are six amino
acids and in the first extracellular domain of hCCR3 that
differ with the RhCCR3 (Fig. 1A). In the HRRR chimeric
receptor, the six different amino acids were individually
mutated to the corresponding amino acid in the rhesus
macaque CCR3 sequence (T13P, Y17D, V20M, T29V,
R30G, M33I). Cells expressing the T13P or the V20M
mutation completely ablated coreceptor activity in the HRRR
chimeric CCR3 for both HIV-1ADA and HIV-1YU-2 (Table 2).
HRRR receptors containing the other four mutations had
coreceptor activity similar to HRRR and wild-type hCCR3.
The five non-homologous amino acids in the third
domain of the RRHR chimeric receptor were individually
mutated to the corresponding amino acid in the rhesus
macaque CCR3 sequence (E173G, E176K, E179P, L186I,
E189Q). Each R5 isolate infected cells expressing hCD4
and any of the mutant chimeric RRHR receptors except,
E179P (Table 2). Lastly, cells expressing mutated chimericFig. 3. Analysis of the levels of HIV-1 coreceptor activities displayed by
chimeric CCR3 expressing one rhesus macaque extracellular domain in a
human CCR3 backbone. All cells expressed hCD4 and one of the CCR3
molecules. Coreceptor activity was normalized to 100% for hCCR3. Data
are represented as the average of three independent experiments with
standard deviations. Panel A: coreceptor activity was assayed for HIV-1YU-2.
Panel B: coreceptor activity was assayed for HIV-1ADA. Panel C: coreceptor
activity was assayed for HIV-189.6.
Fig. 4. Analysis of the levels of HIV-1 coreceptor activities displayed by
chimeric CCR3 expressing two human extracellular domains and two
rhesus macaque extracellular domains. All cells expressed hCD4 and one of
the CCR3 molecules. Coreceptor activity was normalized to 100% for
hCCR3. Data are represented as the average of three independent
experiments with standard deviations. Panel A: coreceptor activity was
assayed for HIV-1YU-2. Panel B: coreceptor activity was assayed for HIV-
1ADA. Panel C: coreceptor activity was assayed for HIV-189.6.
Table 2
Analysis of the levels of HIV-1 coreceptor activities by mutant CCR3
Receptors HIV-1YU-2 HIV-1ADA HIV-189.6
hCD4 0.0 F 0.0 0.0 F 0.0 0.0 F 0.0
hCD4 + hCCR5 110.0 F 2.0 105.0 F 3.0 110.0 F 1.0
hCD4 + hCCR3 100.0 F 0.0a 100.0 F 0.0 100.0 F 0.0
hCD4 + RhCCR3 0.0 F 0.0 0.0 F 0.0 0.0 F 0.0
ECD-1
hCD4 + HRRR 98.0 F 1.0 96.0 F 4.0 N.T.b
hCD4 + T13P 8.0 F 7.0 5.0 F 3.0 N.T.
hCD4 + Y17D 96.0 F 4.0 99.0 F 4.0 N.T.
hCD4 + V20M 5.0 F 1.0 8.0 F 2.0 N.T.
hCD4 + T29V 94.0 F 0.5 99.0 F 0.0 N.T.
hCD4 + M33I 94.0 F 0.5 97.0 F 3.0 N.T.
hCD4 + R30G 94.0 F 0.0 94.0 F 2.0 N.T.
ECD-3
hCD4 + RHRR 100.0 F 0.0 101.0 F 5.0 N.T.
hCD4 + E173G 101.0 F 0.5 98.0 F 3.0 N.T.
hCD4 + E176K 102.0 F 0.5 100.0 F 3.0 N.T.
hCD4 + E179P 0.0 F 0.0 5.0 F 2.0 N.T.
hCD4 + L180I 97.0 F 4.0 99.0 F 3.0 N.T.
hCD4 + E1189Q 97.0 F 4.0 99.0 F 4.0 N.T.
ECD-4
hCD4 + RRRH 100.0 F 0.0 100.0 F 0.0 100.0 F 0.0
hCD4 + S263T 97.0 F 2.0 100.0 F 2.0 5.0 F 1.0
hCD4 + I267V 97.0 F 3.0 99.0 F 3.0 5.0 F 1.0
hCD4 + N271L 5.0 F 1.0 9.0 F 5.0 1.0 F 0.5
a Relative coreceptor activity normalized to hCCR3 for each virus isolate.
b N.T. = not tested.
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tor activity (Table 2). Cells expressing the N271L mutation
did not confer coreceptor activity in RRRH for the R5
isolates (Table 2). In contrast, the S263T and I267V
mutations had no effect on the ability of the RRRH to
mediate entry by the R5 strains.
The HIV-189.6 isolate was also tested for the ability to use
the RRRH chimera because this was the only receptor of the
set that was able to confer coreceptor activity in the
RhCCR3 backbone for the dual-tropic isolate (Fig. 2C).
Interestingly, all three mutations knocked out the coreceptor
activity of RRRH (Table 2). Once again these results
indicate that the HIV-189.6 is more sensitive to changes in
hCCR3 than the R5-tropic isolates.Discussion
In vivo, hCCR5 and hCXCR4 are the predominate
coreceptors that interact with the HIV-1 envelope, resulting
in conformational changes in Env, which lead to fusion of the
viral and cell membranes and thus entry of the virus into the
cytoplasm (Ross et al., 1999). Several members of the
chemokine receptor family can mediate coreceptor activity
for HIV-1 as demonstrated by in vitro assays (Ross et al.,
1999). However, their roles in HIV-1 pathogenesis in vivo
remain controversial. To better define the regions on hCCR3
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hCCR3 and the non-permissive RhCCR3 were constructed
(Fig. 1) and tested for coreceptor activity. Despite that,
RhCCR3 and hCCR3 have 327 identical amino acids (92%)
out of a total of 355, RhCCR3 was unable to mediate HIV-1
infection (Fig. 3 and (Sol et al., 1998)). The lack of RhCCR3
coreceptor activity cannot be explained by a lower cell surface
expression compared to hCCR3 (Table 1).
Any chimeric CCR3 that contained two human CCR3
ECDs served as an efficient coreceptor for HIV-1YU-2 or
HIV-1ADA (Fig. 4). These M-tropic isolates were able to
interact functionally with CCR3 receptors expressing the
first, third, and fourth human ECD in the RhCCR3
backbone (HRRR, RRHR, RRRH) (Fig. 2), as well as
RhCCR3-based receptors containing the first, second, and
fourth ECD of hCCR3 (RHHH, HRHH, HHHR) (Fig. 3). In
both cases, the substitution of the fourth ECD yielded
activity for all three isolates, albeit at lower levels than the
other active chimeras. These envelopes interacted with the
extracellular domains of hCCR3 similar to the interactions
with the ECDs of hCCR5 (Atchison et al., 1996; Bieniasz et
al., 1997; Kuhmann et al., 1997; Picard et al., 1997; Ross et
al., 1998; Speck et al., 1997).
Interestingly, the R5X4 isolate, HIV-189.6, was more
sensitive to changes in the CCR3 extracellular domains than
the R5 viruses. The third and fourth ECDs of CCR3,
together or independently, were required to confer corecep-
tor activity for the R5X4 strain (Fig. 4). These results
confirm and extend previous findings (Alkhatib et al., 1997;
Sol et al., 1998). In addition, using a different set of
chimeras (hCXCR4/hCXCR2), Lu et al. (1997) demonstra-
ted that, for HIV-189.6, ECD-4, and to a lesser extent ECD-3,
of hCXCR4 are essential for coreceptor activity. The
sensitivity of this envelope to changes in coreceptor
domains may be due, in part, to constraints on its flexibility
imposed by its ability to use both hCXCR4 and hCCR5.
Curiously, there were some inconsistencies that demon-
strated the complexity of the interactions between the
various extracellular domains. For example, both hCCR3
(HHHH) and HRRH efficiently served as coreceptors for
both R5 isolates (Table 2), however, the HHRH receptor had
significantly impaired coreceptor activity (Fig. 3). In
contrast, the RRRH receptor is fully active (Fig. 2).
Therefore, even though the RhCCR3 (RRRR) is unable to
efficiently serve as a coreceptor for HIV-1, the RhCCR3
ECDs, in the context of the chimeras described in this study,
can participate in coreceptor activity.
The hCCR3/RhCCR3 chimeras were constructed using
unique restriction enzyme sites that resulted in not only the
exchange of the extracellular domains, but also the
exchange of transmembrane and cytoplasmic regions. Even
though the chimeric receptor strategy has been described in
several previous studies to identify critical regions in ECDs
necessary for coreceptor activity (Bieniasz et al., 1997;
Chabot and Broder, 2000; Lu et al., 1997; Picard et al.,
1997; Ross et al., 1998; Sol et al., 1998), the introduction ofamino acid changes in non-ECD regions may have played a
role in coreceptor function, possibly by contributing to
either (1) the overall conformational structure of the receptor
or (2) the ability to bind to the envelope (Doranz et al.,
1999). However, this may not be as large a concern in this
study, compared to studies using chimeras composed of
non-homologous coreceptors (i.e., hCCR1/hCCR3 (Alkha-
tib et al., 1997) or CCR5/CCR2b (Atchison et al., 1996))
due to the limited number of amino acid differences in non-
ECDs of the two CCR3 molecules. Eleven of the 28 amino
acids that differ between hCCR3 and RhCCR3 are in non-
extracellular regions (Fig. 1A) and most are quite con-
servative amino acid changes.
It is important to understand howM-tropic and dual-tropic
isolates interact with M-tropic receptors (hCCR5 and
hCCR3), however, a direct mutational approach may not be
productive due to the redundancy in the use of the four
extracellular domains by HIV-1 Env, as described above.
Therefore, mutations were introduced into the hCCR3/
RhCCR3 chimeras containing a single human ECD in a
manner similar to hCCR5/mCCR5 chimeras (Ross et al.,
1998) and assayed for coreceptor activity. The residues that
weremutatedwere selected because they differed in the ECDs
between the two CCR3 homologues and therefore, we
expected that these amino acid residues must contribute to
hCCR3 receptor function. None of the mutations affected cell
surface expression of the chimeric CCR3molecules (Table 1).
Interestingly, at least one residue in three of the ECDs
was identified as important for coreceptor activity for the
two R5 viruses tested (Table 2). Two individual substitu-
tions in the first human ECD (T13P and V20M) knocked
out coreceptor function. In addition, one change in the third
ECD (E179P) and one change in the fourth ECD (N271L)
markedly effected coreceptor activity for R5 strains. For
HIV-189.6, only the mutated RRRH receptor was used for
analysis because this chimeric receptor was the only one of
the set that efficiently served as a coreceptor. Interestingly,
mutating any of the three amino acids (S263T, I267V,
N271L) disrupted coreceptor activity (Table 2).
One of the more interesting mutant chimeric CCR3s
assessed was the V20M mutation. This mutation is a
relatively conservative change, since both amino acids are
non-polar and hydrophobic. It is unclear why this point
mutation had an effect on coreceptor function, but it is
possible that the methionine at position 20 was more
efficiently used as a start codon than the natural ATG,
despite the lack of a good Kozak consensus sequence.
Therefore, a significant portion of the expressed receptors
may have had the first 20 amino acids in CCR3 truncated.
The N-terminal eight residues are critical for the natural
ligand of CCR3, eotaxin, to bind and activate hCCR3
(Shinkai et al., 2002). The N-terminus of hCCR5 is contacts
the envelope and mediates subsequent interactions (Rabut et
al., 1998; Trkola et al., 1996). In addition, the naturally
occurring D32/hCCR5 receptor is unable to serve as a
coreceptor for M-tropic isolates (Huang et al., 1996).
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or the E179P mutation in ECD-3 most likely disrupts
protein conformation. Using alanine scanning, residues in
these same regions in hCXCR4 were identified as necessary
for coreceptor activity (Chabot and Broder, 2000). A similar
region was identified in hCCR5 (Doranz et al., 1999; Dragic
et al., 1996; Rabut et al., 1998; Ross et al., 1998) and this
region appears critical for determining T and M-tropism
(Chabot and Broder, 2000). Negatively charged residues in
the amino terminal domain of hCCR5 and hCXCR4 are
critical for coreceptor activity (Chabot and Broder, 2000;
Doranz et al., 1999; Dragic et al., 1996; Kuhmann et al.,
1997, 2000) and that substitutions of these residues affect
the ability of gp120 to bind efficiently to hCCR5, probably
by reducing the affinity of the gp120-coreceptor interac-
tions. The aspartic acid residues in the hCCR3/RhCCR3
chimeras were not mutated in this study, however, four of
the five residues mutated in the third domain of the RRHR
receptor were negatively charged glutamic acids (Fig. 1).
The only mutation of a glutamic acid residue in ECD-3 that
interfered with coreceptor activity was E179P, which can be
explained by the disruption of the conformational structure.
Therefore, the charged residues in ECD-3 of hCCR3 may
not play a significant role in binding of the HIV-1 Env to
this coreceptor.
Lastly, the only residue in the fourth extracellular domain
identified as critical for R5 viruses was N271L. The
substitution of this hydrophobic amino acid for a polar
amino acid may disrupt the integrity or affinity of Env
binding to the molecule, which results in an imbalance in
the net charge of ECD-4. The other mutations (I267V and
S263T) are relatively conservative changes, and not
surprisingly, did not affect CCR3 coreceptor activity.
However, mutation of any of the three residues in ECD-4
knocked out coreceptor activity for HIV-189.6, once again
demonstrating the high level of sensitivity of this dual-tropic
envelope to changes in the coreceptor sequence.
This report indicates that similar to its interactions with
hCXCR4 and hCCR5, the HIV-1 envelope uses multiple
extracellular domains of hCCR3 to enter into human cells.
The hCCR3 is one of many identified coreceptors for HIV-1
in vitro (Philpot, 2003; Ross et al., 1999). Controversially,
hCCR3 has been associate with in vivo infection and has
been implicated in HIV-1 infection in the CNS and AIDS
(Gorry et al., 2003; Martin-Garcia et al., 2002). A thorough
understanding of the interaction between HIV-1 envelope
and hCCR3, in addition to hCCR5 and hCXCR4, may be
needed to prevent viral spread.Material and methods
Cell culture
Human embryonic kidney cells, 293T, were maintained
in complete Dulbecco Modified Eagle Medium (DMEM)supplemented to contain 10% heat-inactivated fetal bovine
serum (FBS) (Atlanta Biologicals, Atlanta, GA, USA), 4
mM l-glutamine, and 0.4 mg/l gentamicin. Cells were
incubated at 37 8C in a humidified 5% CO2 incubator.
Construction of molecular clones and mutants
Mammalian expression plasmids encoding the hCD4,
hCCR3, hCCR5, and hCXCR4 have been described
previously (Ross and Cullen, 1998; Ross et al., 1998).
The rhesus macaque CCR3 (RhCCR3) gene was PCR
amplified and isolated from the peripheral blood mono-
nuclear cells (PBMC) of a healthy donor rhesus macaque
(kind gift from Francis Novembre, Emory University). Each
chimera was constructed using unique restriction sites (Fig.
1). For example, the chimera HRRR was expressed using a
fusion of the human CCR3 sequence (nucleotides 1–228)
and the rhesus macaque CCR3 (nucleotides 229–1065). The
first set of chimeric gene sequences encoded for one
extracellular domain from the hCCR3 and three ECDs from
the RhCCR3. Each chimera was given a designation based
upon the composition of the human and rhesus macaque
extracellular domains. For example, the chimera construct,
HRRR, contains the gene sequences from the first human
extracellular domain in the backbone of rhesus macaque
CCR3. Due to the relative position of the restriction enzyme
sites, HRRR contained, in addition to the first extracellular
domain, the human first and second transmembrane
domains and the first intracellular domain of hCCR3. A
similar strategy was employed to generate single RhCCR3
extracellular domain expressing plasmids, as well as
plasmids that expressed CCR3 proteins containing two
domains from each homologue. Each construct was verified
using unique diagnostic restriction enzyme sites and
sequencing analysis.
All wild-type and mutant chimeras were expressed using
the pBC12/CMV mammalian expression vector (Bieniasz et
al., 1997; Ross and Cullen, 1998; Ross et al., 1998). In
addition, the hemagglutinin (HA) epitope tag was cloned
between the codons coding for amino acid residues 2 and 3
of the each protein. Mutations were introduced into the
coreceptor chimeras by using synthetic oligonucleotide
primers and the Quick Change mutagenesis kit (Stratagene,
La Jolla, CA, USA) and were verified by DNA sequencing.
Point mutants were named according to the nature and
location of the mutation. For example, the Y16D mutation
encodes aspartic acid in place of tyrosine at residue 16 of the
HRRR chimera. The expression plasmids pBC12/CMV/
CD4 and pBC12/HIV/LUC, and the HIV-1 proviral clones
containing the YU-2, ADA, and 89.6 envelope genes, have
been described previously (Ross and Cullen, 1998; Ross et
al., 1998).
The plasmids were amplified in Escherichia coli strain-
DH5a, purified using an endotoxin-free, anion-exchange
resin columns (Quiagen, Valencia, CA, USA) and stored at
20 8C in dH20. Plasmids were verified by appropriate
P.T. Ho et al. / Virology 329 (2004) 109–118 117restriction enzyme digestion and gel electrophoresis. Purity
of DNA preparations was determined by optical density
reading at 260 and 280 nm and therefore, each DNA
plasmid preparation had N50 fg/Ag of endotoxin.
Infection assay
Two sets of 293T cells were plated at a concentration of
approximately 5.0  105 cells/well in a 6-well plate. Cells
were allowed to acclimate for 24 h at 37 8C plus 5% CO2.
The first set of 293T cells was transfected with 2 Ag of the
proviral DNA plasmid (Bieniasz et al., 1997; Ross and
Cullen, 1998; Ross et al., 1998) using 12% lipofectamine
according to the manufacturer’s guidelines (Life Technolo-
gies, Grand Island, NY, USA). A second set of 293T cells
was transfected with plasmids expressing surface receptors
and/or a luciferase reporter plasmid (pHIV-1 LTR-Luc),
which drives expression of the firefly luciferase gene from
the HIV-1 LTR promoter (Ross and Cullen, 1998). Each set
of transfected cells was incubated at 37 8C plus 5% CO2.
The total amount of DNA was maintained at 3 Ag using
pBC12/CMV plasmid as filler. The medium from receptor
expressing cells was aspirated, thoroughly washed, and
overlayed with supernatant from cells transfected with
proviral DNA. Overlayed cells were incubated an additional
48 h at 37 8C plus 5% CO2. Cell lysates were prepared by
adding 300 Al of 1% Triton X-100 lysis buffer (Sigma, St.
Louis, MO, USA). Plates were rocked until cells were
completely detached from the plate. Cells were mixed and
each cell lysate was collected and stored at 80 8C. The
lysates were assayed for luciferase activity according to
manufacture’s instructions (Promega, Madison, WI, USA).
Analysis of CCR3 expression levels
293T cells were transfected with 2 Ag of the coreceptor
expression plasmids, and 72 h later cells were stained with a
murine monoclonal antibody (12CA5, Boehringer Man-
nheim) specific for the HA epitope tag (10 Ag/ml), followed
by fluorescein isothiocyanate-conjugated goat anti-mouse
immunoglobulin G (1:200) (Sigma). Cells were fixed and
surface expression of the chimeric receptors was quantified
by fluorescence-activated cell sorting (FACS).
Statistics
For statistical analysis, the average F standard deviation
of three experiments was determined. A Student’s t test was
employed and differences were considered statistically
significant when P b 0.05.Acknowledgments
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